How Lifetime Evolution of Parkinson’s Disease Could Shape Clinical Trial Design: A Shared Patient–Clinician Viewpoint

Author:

Janssen Daalen Jules M.1ORCID,Gerritsen Aranka1,Gerritse Gijs2,Gouman Jan2,Meijerink Hannie2,Rietdijk Leny E.2,Darweesh Sirwan K. L.1ORCID

Affiliation:

1. Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Center of Expertise for Parkinson & Movement Disorders, 6525 GA Nijmegen, The Netherlands

2. Dutch Parkinson’s Patient Association, P.O. Box 46, 3980 CA Bunnik, The Netherlands

Abstract

Parkinson’s disease (PD) has a long, heterogeneous, pre-diagnostic phase, during which pathology insidiously accumulates. Increasing evidence suggests that environmental and lifestyle factors in early life contribute to disease risk and progression. Thanks to the extensive study of this pre-diagnostic phase, the first prevention trials of PD are being designed. However, the highly heterogenous evolution of the disease across the life course is not yet sufficiently taken into account. This could hamper clinical trial success in the advent of biological disease definitions. In an interdisciplinary patient–clinician study group, we discussed how an approach that incorporates the lifetime evolution of PD may benefit the design of disease-modifying trials by impacting population, target and outcome selection. We argue that the timepoint of exposure to risk and protective factors plays a critical role in PD subtypes, influencing population selection. In addition, recent developments in differential disease mechanisms, aided by biological disease definitions, could impact optimal treatment targets. Finally, multimodal biomarker panels using this lifetime approach will likely be most sensitive as progression markers for more personalized trials. We believe that the lifetime evolution of PD should be considered in the design of clinical trials, and that such initiatives could benefit from more patient–clinician partnerships.

Publisher

MDPI AG

Reference77 articles.

1. Parkinson’s disease;Bloem;Lancet,2021

2. Disease-Associated alpha-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage;Majbour;Neurology,2022

3. Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis;Johnson;Trends Neurosci.,2019

4. Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action;Meinders;J. Park. Dis.,2022

5. Patients as partners in health research: A scoping review;McCarron;Health Expect.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3